SuperworthAnixa Biosciences EPS ANIX
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jul 31, 2026
- −$0.31
- Latest quarter, Q3 FY26
- −$0.08
- Fiscal year 2025
- −$0.34
Anixa Biosciences' earnings per share was −$0.31 over the twelve months to Jul 31, 2026.
In its latest quarter, Q3 FY26, it was −$0.08.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.34 | n/a |
| FY2024 | −$0.39 | n/a |
| FY2023 | −$0.16 | n/a |
| FY2022 | −$0.45 | n/a |
| FY2021 | −$0.44 | n/a |
| FY2020 | −$0.45 | n/a |
| FY2019 | −$0.59 | n/a |
| FY2018 | −$0.77 | n/a |
| FY2017 | −$0.62 | n/a |
| FY2016 | −$0.58 | n/a |
| FY2015 | −$0.18 | n/a |
| FY2014 | −$1.31 | n/a |
| FY2013 | −$1.00 | n/a |
| FY2012 | −$0.25 | n/a |
| FY2011 | −$1.25 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | −$0.08 | n/a | −$0.31 | |
| Q2 FY26 | −$0.07 | n/a | −$0.30 | |
| Q1 FY26 | −$0.08 | n/a | −$0.32 | |
| Q4 FY25 | −$0.08 | n/a | −$0.34 | |
| Q3 FY25 | −$0.07 | n/a | −$0.35 | |
| Q2 FY25 | −$0.09 | n/a | −$0.38 | |
| Q1 FY25 | −$0.10 | n/a | −$0.39 | |
| Q4 FY24 | −$0.09 | n/a | −$0.39 | |
| Q3 FY24 | −$0.10 | n/a | −$0.39 | |
| Q2 FY24 | −$0.10 | n/a | −$0.37 | |
| Q1 FY24 | −$0.10 | −225% | −$0.34 | |
| Q4 FY23 | −$0.09 | n/a | −$0.16 |
Against its peers
Companies in Drug Manufacturers - General nearest Anixa Biosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ANIXAnixa Biosciences | −$0.31 | |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| Peer median | $0.65 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Anixa Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.